Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Takeuchi

Showing results (131-140 of 163) with videos related to

Pageof 17
Sort By:
Neuroimage|November 13, 2020
Differential associations of dopamine synthesis capacity with the dopamine transporter and D2 receptor availability as assessed by PET in the living human brainYasuharu Yamamoto, Keisuke Takahata, Manabu Kubota, et al.
The Lancet. Psychiatry|March 20, 2025
The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophreniaNobuyuki Nomura, Spyridon Siafis, Johannes Schneider-Thoma, et al.
Schizophrenia Research|June 1, 2011
The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspectiveChisa Tsutsumi, Hiroyuki Uchida, Takefumi Suzuki, et al.
Therapeutic Advances in Psychopharmacology|May 28, 2021
Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic studyNobuyuki Nomura, Kohei Kitagawa, Ryuhei So, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 21, 2019
Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review studyParita Shah, Yusuke Iwata, Eric E Brown, et al.
The Journal of ECT|August 28, 2009
Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart reviewShinichiro Nakajima, Takuto Ishida, Rei Akaishi, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 3, 2018
The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) dataMiracle Ozzoude, Shinichiro Nakajima, Eric Plitman, et al.
Schizophrenia Bulletin|February 11, 2017
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysisEric Plitman, Yusuke Iwata, Fernando Caravaggio, et al.
Journal of Alzheimer'S Disease : JAD|November 1, 2015
Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive ImpairmentJun Ku Chung, Eric Plitman, Shinichiro Nakajima, et al.
Psychopharmacology|August 19, 2007
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical settingTakefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, et al.
Pageof 17

Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
Neuroimage|November 13, 2020
Differential associations of dopamine synthesis capacity with the dopamine transporter and D2 receptor availability as assessed by PET in the living human brainYasuharu Yamamoto, Keisuke Takahata, Manabu Kubota, et al.
The Lancet. Psychiatry|March 20, 2025
The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophreniaNobuyuki Nomura, Spyridon Siafis, Johannes Schneider-Thoma, et al.
Schizophrenia Research|June 1, 2011
The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspectiveChisa Tsutsumi, Hiroyuki Uchida, Takefumi Suzuki, et al.
Therapeutic Advances in Psychopharmacology|May 28, 2021
Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic studyNobuyuki Nomura, Kohei Kitagawa, Ryuhei So, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 21, 2019
Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review studyParita Shah, Yusuke Iwata, Eric E Brown, et al.
The Journal of ECT|August 28, 2009
Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart reviewShinichiro Nakajima, Takuto Ishida, Rei Akaishi, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 3, 2018
The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) dataMiracle Ozzoude, Shinichiro Nakajima, Eric Plitman, et al.
Schizophrenia Bulletin|February 11, 2017
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysisEric Plitman, Yusuke Iwata, Fernando Caravaggio, et al.
Journal of Alzheimer'S Disease : JAD|November 1, 2015
Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive ImpairmentJun Ku Chung, Eric Plitman, Shinichiro Nakajima, et al.
Psychopharmacology|August 19, 2007
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical settingTakefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, et al.
Pageof 17